Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy

Journal of Nuclear Medicine

Volumn 44, Issue 1, 2003, Pages 24-29

  Dizendorf, Elena V ^a   Baumert, Brigitta G ^a   Von Schulthess, Gustav K ^a   Lütolf, Urs M ^a   Steinert, Hans C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

18F FDG PET; Radiation management; Radiation therapy; Tumor staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; HUMAN; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SCHOOL CHILD; TREATMENT PLANNING; CHILD; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; NEOPLASM; NOTE; PALLIATIVE THERAPY; PATHOLOGY; PATIENT CARE; PROGNOSIS; RADIOTHERAPY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PALLIATIVE CARE; PATIENT CARE MANAGEMENT; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 0037224978     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Khan FM. Introduction. In: Khan FM, Potish RA, eds. Treatment Planning in Radiation Oncology. Baltimore, MD: Williams & Wilkins; 1998:1-10.
2. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus with correlative lymph node mapping and sampling. Radiology. 1997;202:441-446.
3. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
4. Steinert HC, Huch-Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705-709.
5. 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530-1542.
6. Stumpe K, Uribinell M, Steinert H, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721-728.
7. Moog F, Bangerter M, Diedrichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-481.
8. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med. 2001;42:586-590.
9. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell PJ. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001;28:1751-1757.
10. 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med. 2001;42:1334-1337.
11. 18F-FDG positron emission tomography, computed tomography and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;5:761-767.
12. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med. 1995;36:1747-1757.
13. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999;213:530-536.
14. Gambhir SS, Czemin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature: oncologic applications-melanoma. J Nucl Med 2001;42(suppl 1):1S-93S.
15. Weder W, Schmid R, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886-893.
16. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.
17. 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167-177.
18. Rahn AN, Baum RP, Adamietz IA, et al. Application of FDG-positron emission tomography in radiation treatment planning of head and neck tumors [in German]. Strahlenther Onkol. 1998;174:358-364.
19. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer. 1999;23:105-114.
20. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593-597.
21. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317-324.
22. 18F-fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
23. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma. Cancer. 2001;92:886-895.
24. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
25. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.